65,437 trials
Neoplasms, Oral · Mouth Neoplasms
Primary: Number of Participants With Changes in Putative Tumor Initiating Cell Populations as Defined by Cell Surface CD44 and Intracellular Phospho-ERK1/2 Staining After…
Influenza
Primary: Number of Participants Who Received Influenza Vaccine — 10 Participants
Knee Injuries
Primary: Analgesic Efficacy — 0; 0.1; 0.6; 3.0 units on a scale — p=<0.05
Chronic Obstructive Pulmonary Disease
Primary: Participants Who Experienced Safety Concerns, Where Safety Concerns of Quercetin Supplementation is Indicated by Significant Change From Baseline Measures of Tests…
Cytomegalovirus Infections · Influenza
Primary: Number of Participants From Each Arm Who Received Influenza Vaccine — 33; 37; 8 Participants
Type 1 Diabetes
Primary: Continuous Glucose Monitor (CGM) Glucose Total Area Over the Curve and Less Than 60 mg/dl — 1015; 4375.68 mg/dl/min
Variceal Bleeding
Primary: Proportion of Patients With Eradication of Esophageal Varices — 37; 23 Participants
Psoriasis
Primary: Percentage Change in Endothelial Function Compared to Baseline. — -1.414 percent change — p=<0.05
Evidence of Liver Transplantation · Hyperglycemia · Rejection
Primary: Rejection of Liver Transplant — 17; 20 participants — p=0.709
Smoking
Primary: Employers' KAP — 3.08; 6.06; 3.40 units on a scale
Smoking Cessation
Primary: Smoking Abstinence for 7 Days at Last Contact — 68; 77 participants — p=0.41
Melanoma, Skin
Primary: Number of Genes That Showed Changes in Expression After Vitamin D Treatment — 270 number of genes
Attention Deficit Hyperactivity Disorder
Primary: Physician ADHD Practice Behavior — 0; 0; 6.3; 38.7 percentage of patients — p==.003
Healthy Volunteer Study
Primary: Number of Participants With Adverse Events as a Measure of Safety. Number of Participants With Adverse Events Related to Tolerability. — 0; 4; 5; 1 subjects affected
Primary Fibromyalgia
Primary: Mean Change From Baseline in Weekly Average of Daily Pain Scores at Week 12 — -1.39; -0.95 units on a scale